Kapa Biosystems European Expansion
News Dec 04, 2014
Kapa Biosystems, Inc. has announced the expansion of its commercial operations in Europe with the addition of a direct sales and support channel for the United Kingdom. To help ensure the highest level of customer service and satisfaction, the company will be working closely with Anachem Ltd. to facilitate a seamless transition from the existing distribution partnership to a direct sales and support channel, effective January 1, 2015.
“First and foremost, I would like to thank the team at Anachem for all of their hard work over the last five years,” said Jean-Christophe Hatinguais, Director, International Sales at Kapa Biosystems. “Kapa Biosystems is committed to extending our global reach by increasing our strategic regional investments and building on our continued commercial success. This new team of local sales representatives and application scientists is dedicated to serving and enhancing the experience of our growing customer base in the U.K..”
The new direct sales and support channel in the U.K. is a key part of Kapa’s corporate growth strategy and focus on next-generation sequencing and emerging genomics markets. During the past year, the company has expanded its management team and more than doubled its previous investment to scale enzyme production, quality control, and manufacturing capacity.
Amy Jingzi Liu has been named Commercial Director for the United Kingdom, and will be responsible for leading the new team of sales representatives and application scientists in the region. Ms. Liu brings more than nine years of management, sales, and service experience, including the last five years as the product manager for the Kapa business at Anachem Ltd.
Over the next few months, the company plans on announcing additional key distribution agreements and corporate initiatives to better support the increasing global demand for its product portfolio for PCR, real-time PCR, next-generation sequencing, and molecular diagnostic applications.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.